nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.05.2006 | Original Article

Comparison of ¹¹¹In-DOTA-DPhe¹-Tyr³-octreotide and ¹¹¹In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours

verfasst von: Margarida Rodrigues, Tatjana Traub-Weidinger, Shuren Li, Bettina Ibi, Irene Virgolini

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 5/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Somatostatin receptor scintigraphy with ¹¹¹In-DOTA-DPhe¹-Tyr³-octreotide (¹¹¹In-DOTA-TOC) and ¹¹¹In-DOTA-lanreotide (¹¹¹In-DOTA-LAN) has been used for staging of neuroendocrine tumours (NETs). However, the comparative diagnostic value of these radioligands on a lesion basis has not yet been established. The aim of this study was to compare the diagnostic capacity of ¹¹¹In-DOTA-TOC and ¹¹¹In-DOTA-LAN scintigraphy in patients with NETs, evaluating whether significant differences exist in lesion imaging with these radioligands. Furthermore, dosimetric data were compared.

Methods

Forty-five patients with NETs were investigated with ¹¹¹In-DOTA-TOC and ¹¹¹In-DOTA-LAN scintigraphy. Scintigraphic results were compared with those of conventional imaging and/or surgery in each patient, and also ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG-PET) in 20 patients.

Results

¹¹¹In-DOTA-TOC and ¹¹¹In-DOTA-LAN scintigraphy were true positive in 42/45 (93%) and 39/45 (87%) patients, and imaged 74/91 (81%) and 73/91 (80%) tumour lesions, respectively. ¹¹¹In-DOTA-TOC and ¹¹¹In-DOTA-LAN detected liver metastases in 21 and 14 patients, mediastinal metastases in seven and 11 patients, and bone metastases in two and seven patients, respectively. These radioligands revealed lesions not seen by conventional imaging in seven and eight patients, respectively, or by ¹⁸F-FDG-PET in eight and seven patients, respectively. The estimated tumour absorbed doses for ⁹⁰Y-DOTA-TOC were higher than those for ⁹⁰Y-DOTA-LAN in 14 patients, whereas the opposite was true in 12 patients.

Conclusion

Both ¹¹¹In-DOTA-TOC and ¹¹¹In-DOTA-LAN are suitable for imaging tumour lesions in patients with NETs and can detect lesions that may not be seen by conventional imaging and ¹⁸F-FDG-PET. Compared with ¹¹¹In-DOTA-LAN, ¹¹¹In-DOTA-TOC has a superior diagnostic capacity for liver metastases, but a lower diagnostic capacity for metastatic lesions in mediastinum and bone.

Cremonesi M, Ferrari M, Zoboli S, Chinol M, Stabin MG, Orsi F, et al. Biokinetics and dosimetry in patients administered with ¹¹¹In-DOTA-Tyr³-octreotide: implications for internal radiotherapy with ⁹⁰Y-DOTATOC. Eur J Nucl Med 1999;26:877–86PubMedCrossRef

Kölby L, Wängberg B, Ahlman H, Tisell LE, Fjälling M, Forssell-Aronsson E, et al. Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors. World J Surg 1998;22:679–83PubMedCrossRef

Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [¹¹¹In-DTPA-D-Phe¹]- and [¹²³I-Tyr³]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–731PubMedCrossRef

Virgolini I, Angelberger P, Li S, Yang Q, Kurtaran A, Raderer M, et al. In vitro and in vivo studies of three radiolabelled somatostatin analogues: ¹²³I-Octreotide, ¹²³I-Tyr-3-Octreotide and ¹¹¹In-DTPA-Phe-1-Octreotide. Eur J Nucl Med 1996;23:1388–99PubMedCrossRef

Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. ¹¹¹In- and ⁹⁰Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148–55PubMedCrossRef

Virgolini I, Patri P, Novotny C, Traub T, Leimer M, Füger B, et al. Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr³-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol 2001;12(Suppl 2):41–5CrossRef

Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781–93PubMedCrossRef

Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836–46PubMedCrossRef

Virgolini I, Yang Q, Li S, Angelberger P, Neuhold N, Niederle B, et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumour cell membrane receptors. Cancer Res 1994;54:690–700PubMed

10.

Janson ET, Stridsberg M, Gobl A, Westlin JE, Oberg K. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res 1998;58:2375–8PubMed

11.

Papotti M, Croce S, Macri L, Funaro A, Pecchioni C, Schindler M, et al. Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. Diagn Mol Pathol 2000;9:47–57PubMedCrossRef

12.

Krenning EP, Kooij PP, Bakker WH, Breeman WA, Postema PT, Kwekkeboom DJ, et al. Radiotherapy with a radiolabeled somatostatin analogue, [¹¹¹In-DTPA-D-Phe¹]-octreotide. A case history. Ann N Y Acad Sci 1994;733:496–506PubMedCrossRef

13.

Bernhardt P, Forssell-Aronsson E, Jacobsson L, Skarnemark G. Low-energy electron emitters for targeted therapy of small tumors. Acta Oncol 2001;41:602–8CrossRef

14.

Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997;24:792–5PubMed

15.

Smith-Jones P, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, et al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999;140:5136–48PubMedCrossRef

16.

Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–82PubMedCrossRef

17.

Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E, et al. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumour patients. J Nucl Med 1998;39:1928–36PubMed

18.

Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000;41:1704–13PubMed

19.

Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, et al. Receptor-mediated radiotherapy with⁹⁰Y-DOTA-D-Phe¹-Tyr³-octreotide. Eur J Nucl Med Mol Imaging 2001;28:426–34CrossRef

20.

Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq ⁹⁰Y-DOTATOC. J Nucl Med 2002;43:610–6PubMed

21.

Loevinger R, Budinger T, Watson E. MIRD primer for absorbed dose calculations. Society of Nuclear Medicine, 1998

22.

Mansi L. From the magic bullet to an effective therapy: the peptide experience. Eur J Nucl Med Mol Imaging 2004;31:1393–8PubMedCrossRef

23.

Jais P, Terris B, Ruszniewski P, LeRomancer M, Reyl-Desmars F, Vissuzaine C, et al. Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours. Eur J Clin Investig 1997;27:639–44CrossRef

24.

Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996;37:912–6PubMed

25.

Dorr U, Frank-Raue K, Raue F, Sautter-Bihl ML, Guzman G, Buhr HJ, et al. The potential value of somatostatin receptor scintigraphy in medullary thyroid carcinoma. Nucl Med Commun 1993;14:439–45PubMedCrossRef

26.

Kurtaran A, Leimer M, Kaserer K, Yang Q, Angelberger P, Niederle B, et al. Combined use of ¹¹¹In-DTPA-D-Phe-1-octreotide (OCT) and ¹²³I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC). Nucl Med Biol 1996;23:503–7PubMedCrossRef

27.

Kwekkeboom DJ, Reubi JC, Lamberts SW, Bruining HA, Mulder AH, Oei HY, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993;76:1413–7PubMedCrossRef

28.

Rodrigues M, Traub-Weidinger T, Leimer M, Li S, Andreae F, Angelberger P, et al. Value of ¹¹¹In-DOTA-lanreotide and ¹¹¹In-DOTA-DPhe¹-Tyr³-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with ¹⁸F-FDG PET. Eur J Nucl Med Mol Imaging 2005;32:1144–51PubMedCrossRef

29.

Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid. Clin Endocrinol 2001;54:641–9CrossRef

30.

Higgins GA, Recant L, Fischman AB. The glucagonoma: surgically curable diabetes. Am J Surg 1979;137:142–8PubMedCrossRef

31.

Prinz RA, Dorsch TR, Lawrence AM. Clinical aspects of glucagon producing islet cell tumors. Am J Gastroenterol 1981;10:58–65

32.

Faiss S, Scherubl H, Riecken EO, Wiedenmann B. Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system. Recent Results Cancer Res 1996;142:193–207PubMed

33.

Oeberg K. Advances in chemotherapy and biotherapy of endocrine tumors. Curr Opin Oncol 1998;10:58–65CrossRef

34.

Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994;93:1321–5PubMedCrossRef

35.

Helisch A, Forster GJ, Reber H, Buchholz HG, Arnold R, Goke B, et al. Pre-therapeutic dosimetry and biodistribution of⁸⁶Y-DOTA-Phe¹-Tyr³-octreotide versus¹¹¹In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31:1386–92PubMedCrossRef

Titel: Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours
verfasst von: Margarida Rodrigues
Tatjana Traub-Weidinger
Shuren Li
Bettina Ibi
Irene Virgolini
Publikationsdatum: 01.05.2006
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 5/2006
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-005-0020-3

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2006

18F-DOPA PET/CT and neuroendocrine tumours

99mTc/188Re-labelled lipid nanocapsules as promising radiotracers for imaging and therapy: formulation and biodistribution

Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results

First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent

PET/CT cardiology: an area whose boundaries are still out of sight

Short fluorodeoxyuridine exposure of different human glioblastoma lines induces high-level accumulation of S-phase cells that avidly incorporate 125I-iododeoxyuridine